Abstract:Objective:To investigate the role and mechanism of nicotinamide riboside in obesity-related lipotoxic cardiomyopathy.Methods:Male C57BL/6N mice at 8 weeks of age were randomly divided into the normal diet group (control group), high-fat diet group, and high-fat diet with nicotinamide ribose group ( n=10 each). The mice on high-fat diet were modeled for obese mice lipotoxic cardiomyopathy over a24-week feeding. The mice in the high-fat diet with nicotinamide ribose group were administered with 40 mmol/L nicotinamide ribose in drinking water for 12 weeks on top of the high-fat diet. After modeling, all mice were measured for blood pressure of the caudal artery, collected of peripheral blood samples for testing of blood sugar, and lipids, and evaluated for heart function by echocardiography. Then the mice hearts were harvested and subjected to pathological and molecular biological studies. The heart weight and tibia length of the mice were measured by gross photography. The area of mice cardiomyocytes was quantified by staining with wheat germ agglutinin (WGA). Picrosirius red (PSR) staining was used to show the myocardial fibrosis in mice such that the effect of nicotinamide riboside on mice myocardial remodeling was evaluated. The lipid droplets infiltration in mice cardiomyocytes was examined by transmission electron microscopy. The protein expression levels of Sirt1 and Serca2a in mice cardiomyocytes were detected by Western blotting. Results:Compared with the control group, the mice on high-fat diet presented significant increases in body weight, systolic blood pressure, diastolic blood pressure, total cholesterol, triglyceride and LDL-c levels (all P<0.05), and the elevation in these indicators indiced by high fat diet was alleviated by the addition of nicotinamide riboside (all P<0.05). The heart rate and blood sugar level in mice were not affected by high-fat diet with or without nicotinamide riboside. Compared with the control group, the mice on high-fat diet had higher or greater left ventricular ejection fraction and lower ratio of E to A peaks (E/A) on echocardiograpy (both P<0.05), and addition of nicotinamide riboside increased the left ventricular ejection fraction and E/A ratio (both P<0.05). Compared with the control group, the mice on high-fat diet had higher or greater ratio of heart weight to tibia length, cross-sectional area and collagen contents in cardiomyocytes of the left ventricle (all P<0.05), whereas addition of nicotinamide riboside was found to inhibit the myocardial hypertrophy and fibrosis as described above (all P<0.05). Compared with the control group, high-fat diet led to a significant increase in deposition of lipid droplets in the left ventricular myocardium[ (13.8±0.86) /100 μm 2 vs (4.7±0.51) /100 μm 2, P<0.05], while nicotinamide ribose could alleviate such lipid-induced myocardial fibrosis[ (6.2±0.77) /100 μm 2 vs (13.8±0.86) /100 μm 2, P=0.021]. Western blotting showed lower protein expression levels of Sirt1 in the lipotoxic myocardial tissues and sarco (endo) plasmic reticulum Ca 2+-ATPase (Serca2a), along with increased acetylation of Serca2a in mice on high-fat diet compared with the control group (all P<0.05), while nicotinamide riboside was shown to increase Sirt1 and Serca2a expression and promote Serca2a deacetylation (all P<0.05) . Conclusion:Nicotinamide riboside may alleviate high fat-induced lipotoxic cardiomyopathy by promoting Sirt1-mediated deacetylation of Serca2a.

Riboflavin ameliorates pathological cardiac hypertrophy and fibrosis through the activation of short-chain acyl-CoA dehydrogenase

Riboflavin Ameliorates Mitochondrial Dysfunction Via the AMPK/PGC1α/HO‑1 Signaling Pathway and Attenuates Carbon Tetrachloride‑induced Liver Fibrosis in Rats.

Riboflavin Alleviates Cardiac Failure In Type I Diabetic Cardiomyopathy

Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins.

Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats

Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis

Abstract 298: Flavin Containing Monooxygenase 2 in Cardiac Fibrosis

Riboflavin attenuates myocardial injury via LSD1-mediated crosstalk between phospholipid metabolism and histone methylation in mice with experimental myocardial infarction

RTA 408 Ameliorates Diabetic Cardiomyopathy by Activating Nrf2 to Regulate Mitochondrial Fission and Fusion and Inhibiting NF-κB-mediated Inflammation.

Voltage-dependent anion channel 1 (VDAC1) overexpression alleviates cardiac fibroblast activation in cardiac fibrosis via regulating fatty acid metabolism

Changes in short-chain acyl-coA dehydrogenase during rat cardiac development and stress

LTBP2 Knockdown Ameliorates Cardiac Fibrosis and Apoptosis via Attenuating NF‐κB Signaling Pathway and Oxidative Stress in Mice with Cardiac Hypertrophy

Activated FMS‐like Tyrosine Kinase 3 Ameliorates Angiotensin II‐induced Cardiac Remodelling

Targeted inhibition of Focal Adhesion Kinase Attenuates Cardiac Fibrosis and Preserves Heart Function in Adverse Cardiac Remodeling

Alarin alleviated cardiac fibrosis via attenuating oxidative stress in heart failure rats

Short-chain Acyl-Coa Dehydrogenase is a Potential Target for the Treatment of Vascular Remodelling

Small-molecule 7,8-dihydroxyflavone counteracts compensated and decompensated cardiac hypertrophy via AMPK activation

Role of nicotinamide riboside in lipotoxic cardiomyopathy: a mechanistic study

Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway

Riboflavin Reduces Pro-Inflammatory Activation of Adipocyte-Macrophage Co-culture. Potential Application of Vitamin B2 Enrichment for Attenuation of Insulin Resistance and Metabolic Syndrome Development

Flavin Containing Monooxygenase 2 Prevents Cardiac Fibrosis via CYP2J3-SMURF2 Axis